Exploiting the pharmacokinetic and pharmacodynamic properties of bile acid receptor agonists to treat liver disease

利用胆汁酸受体激动剂的药代动力学和药效学特性来治疗肝病

• 批准号: nhmrc : 1087297
• 负责人: Dr Lionel Hebbard
• 金额: $ 43.61万
• 依托单位: Australian National University
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2015
• 资助国家: 澳大利亚
• 起止时间: 2015-01-01 至 2018-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/exploiting-pharmacokinetic-pharmacodynamic-liver-disease/519171
• 关键词: Exploiting; pharmacokinetic; pharmacodynamic; properties; bile

We have generated preliminary data suggesting that chemicals made by the liver, called bile acids, act on fat cells to release a hormone called adiponectin. In liver disease adiponectin has favorable effects, including reducing liver inflammation and fibrosis (scarring). By using drugs that mimic the action of bile acids we expect that adiponectin production by fat cells can be increased, creating a new way to treat patients with chronic liver diseases.

我们已经产生了初步的数据，表明肝脏产生的化学物质，称为胆汁酸，作用于脂肪细胞，释放一种称为脂联素的激素。在肝脏疾病中，脂联素具有良好的效果，包括减少肝脏炎症和纤维化（瘢痕形成）。通过使用模拟胆汁酸作用的药物，我们期望脂肪细胞产生的脂联素可以增加，从而创造一种治疗慢性肝病患者的新方法。